Predictive Oncology Inc. (NASDAQ:POAI) announced that it has appointed Pamela Bush as its chief business officer to lead all business development, partnering and growth strategies for the company.
As a key member of the executive team, the company said Bush will spearhead its strategic, operational and financial planning initiatives for both existing customers and emerging new markets. She will work closely with senior management in leveraging and expanding its portfolio of proprietary solutions to advance drug discovery and enable oncology drug development for the company’s biopharma partners.
“In terms of scientific intelligence, industry insight and understanding the business of biopharma, Pamela is at the top of her game,” Predictive Oncology’s chairman and CEO Raymond Vennare said in a statement. “She honed these skills over twenty years of experience analyzing emerging markets in life sciences, capital formation for early-stage companies and, most recently, leading business development efforts for Eli Lilly & Company.”
READ: Predictive Oncology adds Dr Robert F. Murphy to its scientific advisory board
The company noted that Bush previously served as its senior vice president of strategic sales and business development. In that role, she was instrumental in guiding the company’s strategic direction, expanding its product offerings and launching commercialization efforts for the company’s flagship technology platform.
“We have the power to change the way drugs are discovered and developed. I’m looking forward to further impacting the future of oncology drug discovery and driving adoption of solutions that can move compounds into clinical trials faster and with higher confidence,” Bush noted. “These efforts collectively benefit our partners, investors and other stakeholders, but most importantly, cancer patients waiting for therapies to be developed.”
The company said Bush brings more than twenty years of experience in venture creation, finance and business development in the life sciences industry. Before joining Predictive Oncology in December of 2021, she worked at Eli Lilly & Company in various roles including corporate business development, finance and patient services.
She also served as the director of immunology at Lilly Patient Services, Eli Lilly & Company, primarily focusing on managing vendor performance and relationships, as well as negotiating contracts and finding workflow efficiencies. Before that, Bush served as director of corporate business development at Eli Lilly & Company. She was also the founder and managing partner of BluGene Consulting, a consultancy supporting emerging life science companies that focused on new client acquisition and private investor fundraising. Throughout her career, she has supported the creation and growth of more than 100 life sciences start-ups, the company said.
Bush currently serves on the board of directors for Cvergenx, is a frequent presenter on oncology drug discovery and serves in various volunteering and mentorship roles. She earned her PhD in Biology from Carnegie Mellon University (CMU) and her MBA from CMU’s Tepper School of Business.
Predictive Oncology is focused on applying artificial intelligence (AI) to develop optimal cancer therapies, which can ultimately lead to more effective treatments and improved patient outcomes.
Contact the author at stephen.gunnion@proactiveinvestors.com